Brimonidine · Alphagan, Alphagan P

What is Brimonidine?

Brimonidine is a selective alpha-2 adrenergic receptor agonist administered as an ophthalmic solution. It reduces intraocular pressure by decreasing aqueous humor production and increasing uveoscleral outflow.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as

Alphagan, Alphagan P, Brimonidine Tartrate, Lumify Redness Reliever Eye Drops, NSC-318825, UK-14304, Lumify

Drug type

Small molecule

Targets

alpha-2 adrenergic receptor (ADRA2A)

Mechanism

Agonist of alpha-2 adrenergic receptor (ADRA2A)

Pathways

aqueous humor production, uveoscleral outflow

Therapy area

Ophthalmology

Developer

Allergan

In trials of

BHC, OCGN

FDA status

Approved as Alphagan, Alphagan P, Brimonidine Tartrate (September 6, 1996), NDA020613 · FDA label

UNII

E6GNX3HHTE

✅ FDA-approved uses

• Reduction of elevated intraocular pressure in open-angle glaucoma or ocular hypertension (Alphagan P)
• Reduction of elevated intraocular pressure in open-angle glaucoma or ocular hypertension (Brimonidine Tartrate)

From the indications section of the FDA label (version of Sep 18, 2025). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Dry EyeOcular Redness

Other drugs acting on ADRA2A

Sources

• FDA label (DailyMed)
• FDA label Lumify Redness Reliever Eye Drops (2026-03-31), indications
• FDA label Alphagan P (2025-09-18), indications
• FDA label Brimonidine Tartrate (2025-09-18), indications
• NCI Thesaurus
• ClinicalTrials.gov NCT03418727
• ClinicalTrials.gov NCT03418727
• ClinicalTrials.gov NCT06803654

Updated Oct 3, 2026.